title: Hyaluronic acid hydrogel modified with nogo-66 receptor antibody and poly-L-lysine to promote axon regrowth after spinal cord injury.
abstract: The biomaterials used for central nervous system injury require not only interacting with specific cell adhesion but also specific growth factor receptors to promote nerve regeneration. In this study, hyaluronic acid (HA)-based hydrogels modified with poly-L-lysine (PLL) and nogo-66 receptor antibody (antiNgR) (HA-PLL/antiNgR) were administered to rats after lateral hemisection of the spinal cord. Anti-neurofilament positive axons were found to extend into the HA-PLL/antiNgR hydrogel at 8 weeks after implantation, which shows significant difference compared with HA-PLL or blank control group. Electron micrographs of implanted hydrogels showed that there were more cells and normal axons with myelin in the HA-PLL/antiNgR implant than that of HA-PLL hydrogel. The antiNgR grafted on HA hydrogels could be detected for 8 weeks after transplantation in vivo. All of these properties may facilitate HA-PLL/antiNgR hydrogels to become a promising scaffold for repairing spinal cord injury. Nevertheless, both two kinds of modified hydrogels (HA-PLL/antiNgR and HA-PLL) showed remarkable advantages in supporting angiogenesis, and simultaneously inhibiting the formation of glial scar.
authors: Department of Materials Science and Engineering, Tsinghua University, Beijing, People's Republic of China.
authors: Yue-Teng
authors: YT
authors: Wei
authors: Yu
authors: Y
authors: He
authors: Chang-Lei
authors: CL
authors: Xu
authors: Ying
authors: Y
authors: Wang
authors: Bing-Fang
authors: BF
authors: Liu
authors: Xiu-Mei
authors: XM
authors: Wang
authors: Xiao-Dan
authors: XD
authors: Sun
authors: Fu-Zhai
authors: FZ
authors: Cui
authors: Qun-Yuan
authors: QY
authors: Xu
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D001369:Axons / Q000187:drug effects / Q000502:physiology*; D058851:GPI-Linked Proteins; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D020100:Hydrogels / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use; D020007:Implants, Experimental; D009185:Myelin Proteins; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009416:Nerve Regeneration / Q000187:drug effects; D000070816:Nogo Receptor 1; D011107:Polylysine / Q000627:therapeutic use*; D051381:Rats; D011956:Receptors, Cell Surface; D018000:Receptors, Peptide / Q000276:immunology*; D013119:Spinal Cord Injuries / Q000628:therapy*; D054457:Tissue Scaffolds / Q000737:chemistry
chemical_list: D000906:Antibodies; D058851:GPI-Linked Proteins; D020100:Hydrogels; D009185:Myelin Proteins; D000070816:Nogo Receptor 1; D011956:Receptors, Cell Surface; D018000:Receptors, Peptide; C486581:Rtn4r protein, rat; D011107:Polylysine; D006820:Hyaluronic Acid